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Syndromic management of sexually-transmitted infections and the threat of untreatable Mycoplasma 
genitalium  
Lancet Infectious Diseases 2018; 18(3): 251–252. http://dx.doi.org/10.1016/S1473-3099(18)30080-X 
Takashi Deguchi1 describes issues in syndromic management of sexually-transmitted infections (STIs) 
and in particular treatment of Mycoplasma genitalium, which shows increasing drug resistance, especially 
in Asia-Pacific, and may become the first untreatable STI.2 Widespread syndromic use of azithromycin has 
increased macrolide resistance in several bacterial STIs, and the evidence that macrolide resistance is less 
likely to develop with an “extended” azithromycin regimen as suggested by Deguchi1 is not strong.3 We 
clearly need to replace syndromic approaches with aetiologic management, which will be facilitated by 
point-of-care tests, which also need to determine drug-resistance profiles for STIs such as M. genitalium 
and N.gonorrhoeae.4 
However, there is an urgent need to establish guidelines for testing, to avoid widespread asymptomatic 
screening for M. genitalium. Although M. genitalium has similar prevalence to C.trachomatis,2 screening 
cannot currently be recommended, due to uncertainty in M. genitalium’s natural history causing large 
uncertainty in the potential benefits,5,6 and concern about selection for antimicrobial resistance, and drug 
toxicity.7 Treatment of M. genitalium is becoming increasingly challenging with resistant cases requiring 
costly drugs, which often have limited availability and are associated with rare but serious side effects.1,2 
Until more-effective and tolerable regimens exist we recommend that sexual health services should 
avoid unnecessarily identifying asymptomatic infections, due to the consequent imperative to treat. The 
only patients where testing for M. genitalium is clearly indicated are (i) those with symptoms (urethritis, 
cervicitis, pelvic inflammatory disease7), and (ii) current partners of index patients infected with M. 
genitalium (even if asymptomatic), to prevent potential reinfection. Multiplex tests detecting M. 
genitalium8 should not be routinely used for sexual health patients without disease since this would create 
a de facto screening programme. However, more information is needed to better-understand M. 
genitalium’s natural history, and unlinked anonymous monitoring of samples from asymptomatic patients 
tested for other STIs would provide valuable information, including rates of M. genitalium co-infection with 
C. trachomatis and N. gonorrhoeae to inform treatment guidelines.6 Treatment of C. trachomatis and N. 
gonorrhoeae with azithromycin will select for resistance in patients co-infected with M. genitalium and this 
use needs to be reviewed. 
To manage M. genitalium effectively, testing should always include the antimicrobial resistance profile: 
antimicrobial resistance is the primary cause of treatment failure with azithromycin and quinolones.3 
Treatment should always be followed by test-of-cure: treatment failures may have a reduced bacterial load 
and mild/unnoticed symptoms, creating an opportunity for propagation of resistance. 
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